Page last updated: 2024-11-06

nebularine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nebularine is a naturally occurring purine nucleoside, isolated from the mushroom Clitocybe nebularis. It has been found to inhibit the growth of various bacteria and viruses. Nebularine is a substrate for adenosine deaminase and is converted to nebularine riboside, a potent inhibitor of the enzyme ribonucleotide reductase. It is also a known inhibitor of the enzyme ornithine decarboxylase. Due to its biological activity, nebularine has been investigated as a potential chemotherapeutic agent. Studies on nebularine have focused on its potential as an anti-cancer drug. The synthesis of nebularine has been achieved through various methods, including the chemical modification of adenine and the use of enzymatic reactions. The compound has also been studied for its potential use in treating certain viral infections and inflammatory diseases.'

nebularine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nebularine : A purine ribonucleoside that is 9H-purine attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID68368
CHEMBL ID1399702
CHEBI ID18255
SCHEMBL ID93409
MeSH IDM0046656

Synonyms (48)

Synonym
bdbm50335291
9-(beta-d-ribofuranosyl)-9h-purine
CHEBI:18255 ,
EU-0100423
purine nucleoside
9h-purine, 9-beta-d-ribofuranosyl-
einecs 208-981-9
brn 0091539
9h-purine, 9beta-d-ribofuranosyl-
LOPAC0_000423
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-purin-9-yl-tetrahydrofuran-3,4-diol
nebularine
550-33-4
C01736
n-d-ribosylpurine
DB04440
NCGC00093846-02
NCGC00093846-01
NCGC00093846-03
D 8296
NCGC00093846-04
CHEMBL1399702 ,
HMS3261E08
4-26-00-01740 (beilstein handbook reference)
b8b604ps4p ,
unii-b8b604ps4p
CCG-204515
LP00423
nebularine [mi]
SCHEMBL93409
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(9h-purin-9-yl)-tetrahydrofuran-3,4-diol;nsc 65423;nebularine;purinosine;nsc65423;st055522
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(9h-purin-9-yl)tetrahydrofuran-3,4-diol
NCGC00261108-01
tox21_500423
MRWXACSTFXYYMV-FDDDBJFASA-N
HB3992
AKOS027327572
9-(beta-d-ribofuranosyl)-9h-purine; 6-deaminoadenosine
mfcd00022819
sr-01000075836
SR-01000075836-1
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(9h-purin-9-yl)oxolane-3,4-diol
Q3874106
AS-35125
DTXSID701015580
SDCCGSBI-0050408.P002
EN300-7400810
Z3002630759

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Mice receiving the combination of tubercidin (or nebularine) plus NBMPR-P or dilazep, as well as those that survived the combination with dipyridamole, appeared healthy and were found to have normal size livers and spleens."( Treatment of schistosomiasis by purine nucleoside analogues in combination with nucleoside transport inhibitors.
Cha, S; el Kouni, MH; Messier, NJ, 1987
)
0.53

Dosage Studied

ExcerptRelevanceReference
" The therapeutic effect was optimal at dosage levels of the protecting agent in excess of those required in nonleukemic mice for protection against the lethal nebularine dosages used, suggesting that the therapeutic effect was due to the joint presence in the leukemic cells of a metabolite of NBMPR-P and nebularine; NBMPR-P protection of the leukemic host against nebularine lethality was necessary for the therapeutic effect to be manifested."( Therapy of mouse leukemia L1210 with combinations of nebularine and nitrobenzylthioinosine 5'-monophosphate.
Lynch, TP; Paran, JH; Paterson, AR, 1981
)
0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fungal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
purine ribonucleosideA ribonucleoside that has a purine moiety as the nucleobase (the R group in the illustration).
purines D-ribonucleosideA purine ribonucleoside that is a purine derivative attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency12.58930.003245.467312,589.2998AID2517
ATAD5 protein, partialHomo sapiens (human)Potency29.08100.004110.890331.5287AID493107
TDP1 proteinHomo sapiens (human)Potency0.36020.000811.382244.6684AID686978; AID686979
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency25.07470.001530.607315,848.9004AID1224819; AID1224820; AID1224821
67.9K proteinVaccinia virusPotency20.38650.00018.4406100.0000AID720579; AID720580
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00110.540617.639296.1227AID2364; AID2528
hemoglobin subunit betaHomo sapiens (human)Potency1.25890.31629.086131.6228AID910
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency14.97630.316212.443531.6228AID902; AID924
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency5.12090.00798.23321,122.0200AID2546; AID2551
survival motor neuron protein isoform dHomo sapiens (human)Potency31.62280.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency9.47010.891312.067628.1838AID1459; AID1487
Integrin beta-3Homo sapiens (human)Potency19.95260.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency19.95260.316211.415731.6228AID924
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, ADENOSINE DEAMINASEMus musculus (house mouse)Ki9.00009.00009.00009.0000AID977610
Adenosine deaminaseHomo sapiens (human)Ki7.00000.00000.30887.0000AID554264
Cytidine deaminaseMus musculus (house mouse)Ki10.00002.00006.000010.0000AID55384
Adenosine deaminase Bos taurus (cattle)Ki11.00000.00000.48937.0000AID33657; AID554263
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (127)

Processvia Protein(s)Taxonomy
adenosine catabolic processAdenosine deaminaseHomo sapiens (human)
inosine biosynthetic processAdenosine deaminaseHomo sapiens (human)
allantoin metabolic processAdenosine deaminaseHomo sapiens (human)
response to hypoxiaAdenosine deaminaseHomo sapiens (human)
trophectodermal cell differentiationAdenosine deaminaseHomo sapiens (human)
liver developmentAdenosine deaminaseHomo sapiens (human)
placenta developmentAdenosine deaminaseHomo sapiens (human)
germinal center B cell differentiationAdenosine deaminaseHomo sapiens (human)
germinal center formationAdenosine deaminaseHomo sapiens (human)
positive regulation of germinal center formationAdenosine deaminaseHomo sapiens (human)
negative regulation of leukocyte migrationAdenosine deaminaseHomo sapiens (human)
mature B cell apoptotic processAdenosine deaminaseHomo sapiens (human)
negative regulation of mature B cell apoptotic processAdenosine deaminaseHomo sapiens (human)
adenosine catabolic processAdenosine deaminaseHomo sapiens (human)
deoxyadenosine catabolic processAdenosine deaminaseHomo sapiens (human)
AMP catabolic processAdenosine deaminaseHomo sapiens (human)
xenobiotic metabolic processAdenosine deaminaseHomo sapiens (human)
smooth muscle contractionAdenosine deaminaseHomo sapiens (human)
cell adhesionAdenosine deaminaseHomo sapiens (human)
response to inorganic substanceAdenosine deaminaseHomo sapiens (human)
positive regulation of heart rateAdenosine deaminaseHomo sapiens (human)
response to purine-containing compoundAdenosine deaminaseHomo sapiens (human)
calcium-mediated signalingAdenosine deaminaseHomo sapiens (human)
positive regulation of B cell proliferationAdenosine deaminaseHomo sapiens (human)
purine nucleotide salvageAdenosine deaminaseHomo sapiens (human)
GMP salvageAdenosine deaminaseHomo sapiens (human)
T cell differentiation in thymusAdenosine deaminaseHomo sapiens (human)
positive regulation of T cell differentiation in thymusAdenosine deaminaseHomo sapiens (human)
regulation of cell-cell adhesion mediated by integrinAdenosine deaminaseHomo sapiens (human)
B cell proliferationAdenosine deaminaseHomo sapiens (human)
T cell activationAdenosine deaminaseHomo sapiens (human)
penile erectionAdenosine deaminaseHomo sapiens (human)
purine-containing compound salvageAdenosine deaminaseHomo sapiens (human)
amide catabolic processAdenosine deaminaseHomo sapiens (human)
AMP salvageAdenosine deaminaseHomo sapiens (human)
positive regulation of smooth muscle contractionAdenosine deaminaseHomo sapiens (human)
dAMP catabolic processAdenosine deaminaseHomo sapiens (human)
dATP catabolic processAdenosine deaminaseHomo sapiens (human)
adenosine metabolic processAdenosine deaminaseHomo sapiens (human)
inosine biosynthetic processAdenosine deaminaseHomo sapiens (human)
xanthine biosynthetic processAdenosine deaminaseHomo sapiens (human)
alpha-beta T cell differentiationAdenosine deaminaseHomo sapiens (human)
positive regulation of alpha-beta T cell differentiationAdenosine deaminaseHomo sapiens (human)
lung alveolus developmentAdenosine deaminaseHomo sapiens (human)
Peyer's patch developmentAdenosine deaminaseHomo sapiens (human)
embryonic digestive tract developmentAdenosine deaminaseHomo sapiens (human)
negative regulation of inflammatory responseAdenosine deaminaseHomo sapiens (human)
positive regulation of calcium-mediated signalingAdenosine deaminaseHomo sapiens (human)
T cell receptor signaling pathwayAdenosine deaminaseHomo sapiens (human)
positive regulation of T cell receptor signaling pathwayAdenosine deaminaseHomo sapiens (human)
leukocyte migrationAdenosine deaminaseHomo sapiens (human)
negative regulation of adenosine receptor signaling pathwayAdenosine deaminaseHomo sapiens (human)
negative regulation of penile erectionAdenosine deaminaseHomo sapiens (human)
thymocyte apoptotic processAdenosine deaminaseHomo sapiens (human)
negative regulation of thymocyte apoptotic processAdenosine deaminaseHomo sapiens (human)
mucus secretionAdenosine deaminaseHomo sapiens (human)
negative regulation of mucus secretionAdenosine deaminaseHomo sapiens (human)
hypoxanthine salvageAdenosine deaminaseHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
adenosine catabolic processAdenosine deaminase Bos taurus (cattle)
cell adhesionAdenosine deaminase Bos taurus (cattle)
nucleotide metabolic processAdenosine deaminase Bos taurus (cattle)
purine ribonucleoside monophosphate biosynthetic processAdenosine deaminase Bos taurus (cattle)
inosine biosynthetic processAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
adenosine deaminase activityAdenosine deaminaseHomo sapiens (human)
protein bindingAdenosine deaminaseHomo sapiens (human)
zinc ion bindingAdenosine deaminaseHomo sapiens (human)
deaminase activityAdenosine deaminaseHomo sapiens (human)
2'-deoxyadenosine deaminase activityAdenosine deaminaseHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
adenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
protein bindingAdenosine deaminase Bos taurus (cattle)
zinc ion bindingAdenosine deaminase Bos taurus (cattle)
2'-deoxyadenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
lysosomeAdenosine deaminaseHomo sapiens (human)
cytosolAdenosine deaminaseHomo sapiens (human)
plasma membraneAdenosine deaminaseHomo sapiens (human)
external side of plasma membraneAdenosine deaminaseHomo sapiens (human)
cell surfaceAdenosine deaminaseHomo sapiens (human)
membraneAdenosine deaminaseHomo sapiens (human)
cytoplasmic vesicle lumenAdenosine deaminaseHomo sapiens (human)
anchoring junctionAdenosine deaminaseHomo sapiens (human)
cytosolAdenosine deaminaseHomo sapiens (human)
external side of plasma membraneAdenosine deaminaseHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
lysosomeAdenosine deaminase Bos taurus (cattle)
cytoplasmic vesicle lumenAdenosine deaminase Bos taurus (cattle)
anchoring junctionAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID116794Percent increase in life span of drug-treated mice relative to tumored, vehicle treated controls at a dose of 6.25 mg/kg ip.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.
AID228918Molar potency ratio was evaluated1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID124815Antitumor activity against P388 tumor in mice, at a dose of 6.25 mg/kg per ip administration.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.
AID33657Binding affinity against calf intestine adenosine deaminase enzyme1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
AID1065714Trypanocidal activity against bloodstream stage of Trypanosoma brucei brucei AnTat1.1E after 72 hrs by WST-1 assay2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID116788Percent increase in life span of drug-treated mice relative to tumored, vehicle treated controls at a dose of 3.13 mg/kg ip.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.
AID124812Antitumor activity against P388 tumor in mice, at a dose of 3.13 mg/kg per ip administration.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.
AID1065706Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by WST-1 assay2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID216185Anti-Herpes simplex virus type-1 activity in vero cells using plaque inhibition assay1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds.
AID584550Cytotoxicity against mouse J774A1 cells2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID584547Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining after 3 hrs measured every hours for up to 7 hrs2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID554263Inhibition of calf intestine adenosine deaminase by Lineweaver-Burk plot analysis2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Investigations into the origin of the molecular recognition of several adenosine deaminase inhibitors.
AID554264Inhibition of adenosine deaminase2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Investigations into the origin of the molecular recognition of several adenosine deaminase inhibitors.
AID584546Inhibition of inosine/L-alanine-induced Bacillus anthracis Sterne 34F2 spore germination pretreated for 15 mins before inosine/L-alanine challenge2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID55384Compound was tested for the inhibitory constant for mouse kidney cytidine deaminase1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1996Biochemistry, Jun-18, Volume: 35, Issue:24
Probing the functional role of two conserved active site aspartates in mouse adenosine deaminase.
AID1811Experimentally measured binding affinity data derived from PDB1996Biochemistry, Jun-18, Volume: 35, Issue:24
Probing the functional role of two conserved active site aspartates in mouse adenosine deaminase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (82)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (36.59)18.7374
1990's22 (26.83)18.2507
2000's10 (12.20)29.6817
2010's13 (15.85)24.3611
2020's7 (8.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.90 (24.57)
Research Supply Index4.44 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.19%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other83 (98.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]